Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies

Drug Discovery Today

Volumn 14, Issue 17-18, 2009, Pages 891-898

  Zhou, Honghui ^a   Davis, Hugh M ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACICLOVIR; ADALIMUMAB; ANTIBIOTIC AGENT; ATORVASTATIN; AZATHIOPRINE; BASILIXIMAB; BRONCHODILATING AGENT; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; PACLITAXEL; PALIVIZUMAB; RITUXIMAB; STEROID; TRASTUZUMAB; UNINDEXED DRUG; USTEKINUMAB;

CLINICAL TRIAL; DRUG ANTAGONISM; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG USE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ANTIBODIES, MONOCLONAL; DRUG INTERACTIONS; HUMANS; RISK ASSESSMENT;

EID: 69749119482     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.05.014     Document Type: Review

References (55)

1. Pharmaceutical Research and Manufacturers of America (2004) Medicines in Development - Biotechnology - Survey, Washington, DC
2. Nagel T., et al. The further evolution of biotech. Nat. Rev. Drug Discov. 2 (2003) 75-79
3. Baumann A. Preclinical development of therapeutic biologics. Expert Opin. Drug Discov. 3 (2008) 289-297
4. Reichert J.M., and Dewitz M.C. Anti-infective monoclonal antibodies: perils and promise of development. Nat. Rev. Drug Discov. 5 (2006) 191-195
5. Mahmood I., and Green M.D. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J. Clin. Pharmacol. 47 (2007) 1540-1554
6. Seitz K., and Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J. Clin. Pharmacol. 47 (2007) 1104-1118
7. Tabrizi M.A., and Roskos L.K. Preclinical and clinical safety of monoclonal antibodies. Drug Discov. Today 12 (2007) 540-547
8. Singer E. Tysabri withdrawal calls entire class into question. Nat. Med. 11 (2005) 359
9. Sharpe A.H., and Abbas A.K. T-cell costimulation-biology, therapeutic potential, and challenges. N. Engl. J. Med. 355 (2006) 973-975
10. Suntharalingam G., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355 (2006) 1018-1028
11. FDAnews Drug Daily Bulletin (2008) FDA Mandates Stronger Fungal Warning on TNF Blockers 5
12. Grönroos P., et al. A medication database-a tool for detecting drug interactions in hospital. Eur. J. Clin. Pharmcol. 53 (1997) 13-17
13. McLeod H.L. Clinically relevant drug-drug interactions in oncology. Br. J. Clin. Pharmcol. 45 (1998) 539-544
14. Dresser G.K., et al. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38 (2000) 41-57
15. Gex-Fabry M., et al. Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions. Drug Saf. 24 (2001) 947-959
16. DeVane C.L. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacol. Bull. 36 (2002) 5-21
17. Chen Y.F., et al. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf. 28 (2005) 67-80
18. Martin J., and Krum H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class-are they clinically relevant?. Drug Saf. 26 (2003) 13-21
19. Rodrigues A.D. Drug-Drug Interactions. 1st ed. (2002), Marcel Dekker
20. Baxter K. Stockley's Drug Interactions. 8th ed. (2007), Pharmaceutical Press
21. Sandson N.B. Drug-Drug Interaction Primer: A Compendium of Case Vignettes for the Practicing Clinician. 1st ed. (2007), American Psychiatric Publishing
22. Litt J.Z. Litt's Drug Eruption Reference Manual including Drug Interactions with CD-ROM. 10th ed. (2004), Taylor & Francis Group
23. Honig P.K., et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269 (1993) 1513-1518
24. Von Moltke L.L., et al. In vitro prediction of the terfenadine ketoconazole pharmacokinetic interaction. J. Clin. Pharmcol. 34 (1994) 1222-1227
25. Keogh A., et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N. Engl. J. Med. 333 (1995) 628-633
26. Merry C., et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11 (1997) F29-F33
27. Williams S.J., and Farrell G.C. Inhibition of antipyrine metabolism by interferon. Br. J. Clin. Pharmacol. 22 (1986) 610-612
28. Williams S.J., et al. Inhibition of theophylline metabolism by interferon. Lancet 8565 (1987) 939-941
29. Okuno H., et al. Depression of drug metabolizing activity in the human liver by interferon-alpha. Eur. J. Clin. Pharmacol. 39 (1990) 365-367
30. Okuno H., et al. Depression of drug-metabolizing activity in the human liver by interferon-beta. Hepatology 17 (1993) 65-69
31. Carelli M., et al. Modulation of constitutive and inducible hepatic cytochrome(s) P-450 by interferon beta in mice. J. Hepatol. 24 (1996) 230-237
32. Hassan M., et al. The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma. Eur. J. Haematol. 63 (1999) 163-170
33. Islam M., et al. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin. Cancer Res. 8 (2002) 2480-2487
34. Weisman M.H., et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin. Ther. 25 (2003) 1700-1721
35. Abbott Laboratories (2008) Approved prescribing information for Humira (adalimumab). Available at: http://www.fda.gov/cder/foi/label/2008/125057s114lbl.pdf. Accessed December 9, 2008
36. Bunescu A., et al. Enhanced Fcγ receptor I, αMβ integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J. Rheumatol. 31 (2004) 2347-2355
37. Tabrizi M.A., et al. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today 11 (2006) 81-88
38. Huang S.M., et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 48 (2008) 662-670
39. Bjornsson T.D., et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J. Clin. Pharmacol. 43 (2003) 443-469
40. Kovarik J.M., et al. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition. J. Clin. Pharmacol. 49 (2009) 212-218
41. Brambell F.W. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 2 (1966) 1087-1093
42. Ghetie V., and Ward E.S. Transcytosis and catabolism of antibody. Immunol. Res. 25 (2002) 97-113
43. Junghans R.P. Finally! The brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol. Res. 16 (1997) 29-57
44. Ober R.J., et al. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11076-11081
45. Zhu Y., et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate-to-severe plaque psoriasis. J. Clin. Pharmacol. 49 (2009) 162-175
46. Aitken A.E., and Morgan E.T. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metabol. Dispos. 35 (2007) 1687-1693
47. Zhou H., et al. 'Cocktail' approaches and strategies in drug development: valuable tool or flawed science?. J. Clin. Pharmacol. 44 (2004) 120-134
48. Fuhr U., et al. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the 'cocktail' approach. Clin. Pharmacol. Ther. 81 (2007) 270-283
49. Thummel K.E., and Wilkinson G.R. In vitro and in vivo drug interactions involving human CYP3A4. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 389-430
50. Zhou H., et al. Absence of a clinically relevant interaction between etanercept and digoxin. J. Clin. Pharmacol. 44 (2004) 1244-1251
51. Hoffman-La Roche (2008). Briefing Document for Tocilizumab Biologic License Application 125276. FDA Arthritis Advisory Committee, July
52. Hoffman-La Roche (2007) Approved prescribing information for Pegasys (Peginterferon alfa-2a). Available at: http://www.fda.gov/cder/foi/label/2007/103964s5120lbl.pdf. Accessed December 9, 2008
53. Sun H., et al. Population pharmacokinetics. A regulatory perspective. Clin. Pharmacokinet. 37 (1999) 41-58
54. Zhou H. Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?. J. Clin. Pharmacol. 46 (2006) 1268-1289
55. Huang S.M., et al. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues. J. Clin. Pharmacol. 39 (1999) 1006-1014